Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq - Seite 2

Through our partnerships with CNS drug development companies, we have already been featured in three publications in 2024. These include partnerships with Novartis, Takeda, and STALICLA SA. We are very proud of these collaborations, and their findings provide the impetus for us to pursue other partnerships in the CNS drug development space. If BNA is integrated into the clinical strategy, we believe that the cost of CNS drug development can be dramatically reduced, can help de-risk critical decision making, and potentially expedite time to approval.

We believe that Firefly’s distinct advantage lies in our expertise in data science and clinical research. For example, our FDA-cleared age-matched normalized database is part of a standardized proprietary database of over 17,000 patients across 12 disorders and illnesses. We believe our database and proprietary technology gives us a strong competitive advantage in developing clinical biomarkers to help fundamentally change how clinicians manage their patients. We ascribe great importance to the value initial accurate diagnosis and effective treatment play in a patient’s overall treatment plan. Furthermore, being in the advantageous position to commercialize BNA supports product development as our database grows with every BNA assessment, further establishing our leadership position in the CNS space.

In closing, I want to extend my appreciation for the hard work and passion exhibited by the entire Firefly team, and I would like to thank our stockholders for their patience and belief in our vision. Without your commitment and support, none of this would have been possible. Today our team is very well positioned to continue its commitment to improving patients’ lives. Your trust and confidence in Firefly have helped us build the remarkable company we have become, and one whose future has never been brighter.

Sincerely,
Jon Olsen
CEO
Firefly Neuroscience, Inc.

¹ Findings presented in 2023 white paper study “Brain Network Analytics (BNA(TM)) in the Psychiatric Practice: Real-Life Data Analysis” by Charlotte Baumeister, Ph.D.

About Firefly
Firefly (Nasdaq: AIFF) is an Artificial Intelligence (“AI”) technology company dedicated to developing groundbreaking neuroscientific solutions that enhance outcomes for patients with mental illnesses and neurological disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA) platform revolutionizes diagnostic and treatment methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has invested approximately $60 million in developing its BNA platform, building a comprehensive database of brain wave tests, securing patent protection, and achieving FDA approval. The Company is now launching the BNA platform commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.